Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mardor, Y.
Right arrow Articles by Cohen, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mardor, Y.
Right arrow Articles by Cohen, J. S.
[Cancer Research 60, 5179-5186, September 15, 2000]
© 2000 American Association for Cancer Research


Experimental Therapeutics

Noninvasive Real-Time Monitoring of Intracellular Cancer Cell Metabolism and Response to Lonidamine Treatment Using Diffusion Weighted Proton Magnetic Resonance Spectroscopy1

Yael Mardor, Ofer Kaplan, Marina Sterin, Jesus Ruiz-Cabello, Elissa Ash, Yiftach Roth, Israel Ringel and Jack S. Cohen2

Advanced Technology Center, Sheba Medical Center, Tel Hashomer 52621, Israel [Y. M., Y. R., J. S. C.]; The Hebrew University, Jerusalem 91120, Israel [M. S., I. R.]; Complutense University, Madrid 28040, Spain [J. R-C.]; Tufts University, Boston, Massachusetts 02111 [E. A.]; and Tel-Aviv Medical Center, Tel-Aviv 64239, Israel [O. K.]

We have used diffusion-weighted proton magnetic resonance spectroscopy (DWMRS) to noninvasively selectively observe only the intracellular metabolites of breast cancer and melanoma cell lines in vitro in real time. Breast cancer cell lines representing different stages in breast cancer progression were chosen for study. Intracellular biochemical profiles of six cell lines perfused in alginate beads were obtained. Spectral differences between groups of cell lines, including choline, lactate, and threonine peaks, were investigated. We also monitored response to the antineoplastic agent, lonidamine (LND), as a function of time and drug concentration in perfused cancer cells. Previous studies reported that this drug induced intracellular acidification and lactate accumulation. Diffusion weighted proton spectra demonstrated a 2- to 9-fold increase in the intracellular lactate signal as a response to LND treatment in several cancer cell lines. These results are consistent with the hypothesis that the principal mechanism of LND in some cancer cells is marked inhibition of lactate transport. Moreover, we have shown that there is a factor of two to three between the response of melanoma cells and that of some types of breast cancer cells. The higher sensitivity of the melanoma cells, as predicted by proton DWMRS, was correlated with changes in water-suppressed magnetic resonance spectra and confirmed by a biological assay. This study demonstrates the feasibility of using DWMRS for monitoring intracellular metabolism and for studying the effects and mechanisms of action of anticancer drugs. We believe that this method can be used for noninvasive clinical applications, such as the differentiation between benign and malignant tissue, real-time monitoring of response to therapy, dose response, and toxicity effects.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. Fang, Q. J. Quinones, T. L. Holman, M. J. Morowitz, Q. Wang, H. Zhao, F. Sivo, J. M. Maris, and M. L. Wahl
The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma
Mol. Pharmacol., December 1, 2006; 70(6): 2108 - 2115.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, et al.
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
J. Clin. Oncol., September 15, 2003; 21(18): 3462 - 3468.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.